CA2819464A1 - Selective glycosidase inhibitors, methods of making inhibitors, and uses thereof - Google Patents

Selective glycosidase inhibitors, methods of making inhibitors, and uses thereof Download PDF

Info

Publication number
CA2819464A1
CA2819464A1 CA2819464A CA2819464A CA2819464A1 CA 2819464 A1 CA2819464 A1 CA 2819464A1 CA 2819464 A CA2819464 A CA 2819464A CA 2819464 A CA2819464 A CA 2819464A CA 2819464 A1 CA2819464 A1 CA 2819464A1
Authority
CA
Canada
Prior art keywords
group
inhibitor
alkyl chains
heteroatom
thiazoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2819464A
Other languages
English (en)
French (fr)
Inventor
Matthew Macauley
David Vocadlo
Garrett Whitworth
Keith Stubbs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Simon Fraser University
Original Assignee
Simon Fraser University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Simon Fraser University filed Critical Simon Fraser University
Publication of CA2819464A1 publication Critical patent/CA2819464A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2819464A 2005-03-01 2006-03-01 Selective glycosidase inhibitors, methods of making inhibitors, and uses thereof Abandoned CA2819464A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65687805P 2005-03-01 2005-03-01
US60/656,878 2005-03-01
CA2599843A CA2599843C (en) 2005-03-01 2006-03-01 Selective glycosidase inhibitors, methods of making inhibitors, and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2599843A Division CA2599843C (en) 2005-03-01 2006-03-01 Selective glycosidase inhibitors, methods of making inhibitors, and uses thereof

Publications (1)

Publication Number Publication Date
CA2819464A1 true CA2819464A1 (en) 2006-09-08

Family

ID=36940808

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2819464A Abandoned CA2819464A1 (en) 2005-03-01 2006-03-01 Selective glycosidase inhibitors, methods of making inhibitors, and uses thereof
CA2599843A Expired - Fee Related CA2599843C (en) 2005-03-01 2006-03-01 Selective glycosidase inhibitors, methods of making inhibitors, and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2599843A Expired - Fee Related CA2599843C (en) 2005-03-01 2006-03-01 Selective glycosidase inhibitors, methods of making inhibitors, and uses thereof

Country Status (7)

Country Link
US (1) US20080287375A1 (https=)
EP (2) EP2436687A1 (https=)
JP (1) JP5154954B2 (https=)
CN (1) CN101208352B (https=)
AU (1) AU2006220187B2 (https=)
CA (2) CA2819464A1 (https=)
WO (1) WO2006092049A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116376875A (zh) * 2023-03-03 2023-07-04 云南师范大学 耐热性提高的n-乙酰氨基葡萄糖苷酶突变体及其应用
CN116555229A (zh) * 2023-05-25 2023-08-08 云南师范大学 N-乙酰氨基葡萄糖苷酶突变体、重组表达载体及菌和应用

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080166323A1 (en) * 2004-04-14 2008-07-10 Uab Research Foundation Activators of Hexosamine Biosynthesis as Inhibitors of Injury Induced by Ischemia or Hermorrhagic Shock
EP2057171A4 (en) * 2006-08-31 2010-04-21 Univ Fraser Simon SELECTIVE GLYCOSIDASE INHIBITORS AND APPLICATIONS THEREOF
CN107253970A (zh) * 2006-08-31 2017-10-17 西蒙·弗雷瑟大学 选择性糖苷酶抑制剂及其用途
GB0622702D0 (en) * 2006-11-15 2006-12-27 Univ Dundee Selective glycosidase inhibitors
US8518903B2 (en) 2007-04-19 2013-08-27 University of Pittsburgh—of the Commonwealth System of Higher Education Use of toll-like receptor-9 agonists
CA2732335A1 (en) 2008-08-01 2010-02-04 Simon Fraser University Selective glycosidase inhibitors and uses thereof
EP2321289A4 (en) * 2008-08-01 2011-11-16 Univ Fraser Simon SELECTIVE GLYCOSIDASE HEMMER AND ITS USE
CA2737267A1 (en) * 2008-09-16 2010-04-08 Simon Fraser University Selective glycosidase inhibitors and uses thereof
US9120781B2 (en) 2010-05-11 2015-09-01 Simon Fraser University Selective glycosidase inhibitors and uses thereof
US9072760B2 (en) 2010-09-24 2015-07-07 University of Pittsburgh—of the Commonwealth System of Higher Education TLR4 inhibitors for the treatment of human infectious and inflammatory disorders
US10668092B2 (en) 2010-09-24 2020-06-02 The John Hopkins University Compositions and methods for treatment of inflammatory disorders
WO2012040719A2 (en) * 2010-09-24 2012-03-29 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Novel tlr4 inhibitors for the treatment of human infectious and inflammatory disorders
TW201249848A (en) 2010-11-08 2012-12-16 Merck Sharp & Dohme Selective glycosidase inhibitors and uses thereof
US8933040B2 (en) 2010-11-08 2015-01-13 Craig A. Coburn Selective glycosidase inhibitors and uses thereof
US8901087B2 (en) * 2010-11-08 2014-12-02 Merck Sharp & Dohme Corp. Selective glycosidase inhibitors and uses thereof
WO2012061972A1 (en) * 2010-11-08 2012-05-18 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
WO2012088425A2 (en) 2010-12-22 2012-06-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Gap junction-enhancing agents for treatment of necrotizing enterocolitis and inflammatory bowel disease
DK2655388T3 (en) * 2010-12-23 2016-09-19 Alectos Therapeutics Inc Selective glykosidaseinhibitorer and uses thereof
WO2012126091A1 (en) * 2011-03-24 2012-09-27 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
WO2012129651A1 (en) 2011-03-31 2012-10-04 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
WO2012129802A1 (en) * 2011-03-31 2012-10-04 Alectos Therapeutics Inc. Pyrano[3,2-d]thiazol derivatives and uses as selective glycosidase inhibitors thereof
WO2013000086A1 (en) 2011-06-27 2013-01-03 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
CN103889996B (zh) * 2011-06-27 2016-02-03 阿列科托斯治疗有限公司 选择性糖苷酶抑制剂及其用途
WO2013000085A1 (en) 2011-06-27 2013-01-03 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
EP2744338B1 (en) * 2011-08-18 2016-04-27 Merck Sharp & Dohme Corp. Selective glycosidase inhibitors and uses thereof
AU2012298949B2 (en) * 2011-08-25 2016-09-22 Merck Patent Gmbh Pyrano [3, 2 - D] [1, 3] thiazole as glycosidase inhibitors
KR102108586B1 (ko) 2012-05-08 2020-05-07 머크 샤프 앤드 돔 코포레이션 투과성 글리코시다제 억제제 및 그의 용도
WO2014032185A1 (en) 2012-08-31 2014-03-06 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
WO2014032188A1 (en) 2012-08-31 2014-03-06 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
WO2014052453A1 (en) 2012-09-25 2014-04-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Oral therapy of necrotizing enterocolitis
WO2014067003A1 (en) 2012-10-31 2014-05-08 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
WO2014100934A1 (en) 2012-12-24 2014-07-03 Merck Sharp & Dohme Corp. Glycosidase inhibitors and uses thereof
WO2014171206A1 (ja) * 2013-04-17 2014-10-23 Yuasa Tomoyuki 糖尿病治療薬の新規なスクリーニング方法
EP3868752A1 (en) 2014-08-28 2021-08-25 Asceneuron SA Glycosidase inhibitors
AU2017222958B2 (en) 2016-02-25 2019-07-18 Asceneuron S. A. Glycosidase inhibitors
SG11201807012QA (en) 2016-02-25 2018-09-27 Asceneuron S A Acid addition salts of piperazine derivatives
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
CN108884078A (zh) 2016-02-25 2018-11-23 阿森纽荣股份公司 糖苷酶抑制剂
WO2019037860A1 (en) 2017-08-24 2019-02-28 Asceneuron S.A. LINEAR INHIBITORS OF GLYCOSIDASE
IL280841B2 (en) 2018-08-22 2024-12-01 Asceneuron S A Succinate and fumarate acid addition salts of piperazine derivatives useful as glycosidase inhibitors
WO2020039027A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Pyrrolidine glycosidase inhibitors
WO2020039028A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Tetrahydro-benzoazepine glycosidase inhibitors
WO2020039029A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Spiro compounds as glycosidase inhibitors
CN114524854B (zh) * 2022-02-25 2023-05-26 中国农业大学 一种糖基芳香环碳苷衍生物及其制备方法与应用
WO2024083820A1 (en) 2022-10-18 2024-04-25 Institut National de la Santé et de la Recherche Médicale Method and composition for determining the level of o-glcnacylation in horses
CN118086249B (zh) * 2024-01-24 2024-12-06 云南师范大学 一种协同提高酶活和热稳定性的n-乙酰氨基葡萄糖苷酶突变体及其制备与应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9818732D0 (en) * 1998-08-27 1998-10-21 Univ Portsmouth Collection of compounds
US6774140B1 (en) * 1999-05-11 2004-08-10 The Scripps Research Institute Iminocyclitol inhibitors of hexoaminidase and glycosidase
WO2002072860A1 (en) * 2001-03-14 2002-09-19 Denki Kagaku Kogyo Kabushiki Kaisha Process for producing hyaluronic acid or its derivative
EP1633356A1 (en) * 2003-05-22 2006-03-15 The Hospital for Sick Children Treatment of tay sachs or sandhoff diseases by enhancing hexosaminidase activity
EP2057171A4 (en) * 2006-08-31 2010-04-21 Univ Fraser Simon SELECTIVE GLYCOSIDASE INHIBITORS AND APPLICATIONS THEREOF
EP2321289A4 (en) * 2008-08-01 2011-11-16 Univ Fraser Simon SELECTIVE GLYCOSIDASE HEMMER AND ITS USE
CA2732335A1 (en) * 2008-08-01 2010-02-04 Simon Fraser University Selective glycosidase inhibitors and uses thereof
CA2737267A1 (en) * 2008-09-16 2010-04-08 Simon Fraser University Selective glycosidase inhibitors and uses thereof
US9120781B2 (en) * 2010-05-11 2015-09-01 Simon Fraser University Selective glycosidase inhibitors and uses thereof
US8933040B2 (en) * 2010-11-08 2015-01-13 Craig A. Coburn Selective glycosidase inhibitors and uses thereof
DK2655388T3 (en) * 2010-12-23 2016-09-19 Alectos Therapeutics Inc Selective glykosidaseinhibitorer and uses thereof
WO2012126091A1 (en) * 2011-03-24 2012-09-27 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
WO2012129651A1 (en) * 2011-03-31 2012-10-04 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116376875A (zh) * 2023-03-03 2023-07-04 云南师范大学 耐热性提高的n-乙酰氨基葡萄糖苷酶突变体及其应用
CN116376875B (zh) * 2023-03-03 2024-02-23 云南师范大学 耐热性提高的n-乙酰氨基葡萄糖苷酶突变体及其应用
CN116555229A (zh) * 2023-05-25 2023-08-08 云南师范大学 N-乙酰氨基葡萄糖苷酶突变体、重组表达载体及菌和应用

Also Published As

Publication number Publication date
AU2006220187B2 (en) 2012-11-08
CN101208352A (zh) 2008-06-25
AU2006220187A1 (en) 2006-09-08
CA2599843A1 (en) 2006-09-08
CN101208352B (zh) 2013-08-07
EP1869060A1 (en) 2007-12-26
EP2436687A1 (en) 2012-04-04
EP1869060A4 (en) 2009-08-12
WO2006092049A1 (en) 2006-09-08
JP5154954B2 (ja) 2013-02-27
EP1869060B1 (en) 2012-08-15
JP2008531604A (ja) 2008-08-14
US20080287375A1 (en) 2008-11-20
CA2599843C (en) 2013-08-27

Similar Documents

Publication Publication Date Title
CA2599843C (en) Selective glycosidase inhibitors, methods of making inhibitors, and uses thereof
EP2322529B1 (en) Selective glycosidase inhibitors and uses thereof
EP2935283B1 (en) Glycosidase inhibitors and uses thereof
CA2816798C (en) Selective glycosidase inhibitors and uses thereof
AU2009276222B2 (en) Selective glycosidase inhibitors and uses thereof
EP2691407B1 (en) Selective glycosidase inhibitors and uses thereof
WO2012061972A1 (en) Selective glycosidase inhibitors and uses thereof
CN107253970A (zh) 选择性糖苷酶抑制剂及其用途
CA2822493A1 (en) Selective glycosidase inhibitors and uses thereof
CA2732336A1 (en) Selective glycosidase inhibitors and uses thereof
AU2009299073A1 (en) Selective glycosidase inhibitors and uses thereof
WO2012126091A1 (en) Selective glycosidase inhibitors and uses thereof
Ayers et al. Nine of 16 stereoisomeric polyhydroxylated proline amides are potent β-N-acetylhexosaminidase inhibitors
WO2012129802A1 (en) Pyrano[3,2-d]thiazol derivatives and uses as selective glycosidase inhibitors thereof
US20130296301A1 (en) Selective glycosidase inhibitors and uses thereof
AU2013200241A1 (en) Selective glycosidase inhibitors, methods of making inhibitors, and uses thereof
Heinonen Rational design and synthesis of chemical probes for O-GlcNAcase and OGT

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20131028

FZDE Discontinued

Effective date: 20171011